June 6, 2014 / 11:02 PM / 4 years ago

U.S. FDA approves BioDelivery's drug for opioid dependence

(Reuters) - BioDelivery Sciences International Inc said it had received U.S. regulatory approval for its drug, Bunavail, to treat opioid dependence.

The company’s shares rose 8.5 percent to $10.85 in extended trading on Friday.

BioDelivery said it expects to launch the drug late in the third quarter ending Sept. 30.

Opioid dependence affects more than 2 million people in the United States.

Reporting by Shailesh Kuber in Bangalore; Editing by Maju Samuel

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below